| Methods |
Single centre randomised placebo controlled study. |
| Participants |
18 CF patients (5.5‐36.3 years, median 15.1). Diagnosis not clear, mean sweat chloride, 74.5 mg/L. One patient had 5T mutation (associated with a milder phenotype). |
| Interventions |
Azithromycin (10 patients) 250 mg twice a week for 12 weeks versus placebo (8 patients). |
| Outcomes |
BPI‐ANCA levels in the blood (a possible marker of inflammation). Also respiratory function. Also secondary outcomes not fully reported (authors contacted). Overall weight gain in both groups, but wide range and differences not reported. |
| Notes |
Israeli study. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Not described. |
| Allocation concealment (selection bias) |
Low risk |
By hospital pharmacy staff independent of trial staff |
| Blinding (performance bias and detection bias)
All outcomes |
Low risk |
Tablets identical in colour and shape. |
| Incomplete outcome data (attrition bias)
All outcomes |
High risk |
3 patients dropped out and were not included in analysis. |
| Selective reporting (reporting bias) |
High risk |
Patients seen at 4, 8 and 12 weeks, but data only reported for week 12. |
| Other bias |
High risk |
Visual analogue scale not validated. |
